Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF
- PMID: 9405310
- DOI: 10.1242/jcs.111.2.237
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF
Abstract
Hepatocyte growth factor, also known as scatter factor, is a pleiotropic cytokine, which stimulates cell motility, invasion, proliferation, survival and morphogenesis, and induces the expression of specific genes by activating its receptor tyrosine kinase. In this work we have isolated, characterized and used as agonists two monoclonal antibodies (mAbs) directed against the extracellular domain of HGF receptor to investigate the requirements for receptor activation and for the different biological responses. The two mAbs display similar affinities, react with epitopes different from the hepatocyte growth factor binding site, and behave as either full or partial agonists. The full agonist mAb (DO-24) triggers all the biological effects elicited by hepatocyte growth factor, namely motility, proliferation, cell survival, invasion, tubulogenesis and angiogenesis. The partial agonist mAb (DN-30) induces only motility. Only the full agonist mAb is able to induce and sustain the expression of urokinase-type plasminogen activator receptor for prolonged periods of time, while both mAbs up-regulate the constitutive expression of urokinase-type plasminogen activator. Both mAbs activate receptor phosphorylation, which, being strictly dependent on mAb bivalence, requires receptor dimerization. Since simple receptor dimerization is not sufficient to trigger full biological responses, we propose that the region on the ss chain of the receptor recognized by the full agonist mAb is crucial for optimal receptor activation.
Similar articles
-
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.Am J Pathol. 1998 Jul;153(1):201-12. doi: 10.1016/S0002-9440(10)65561-7. Am J Pathol. 1998. PMID: 9665481 Free PMC article.
-
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.Cancer Res. 2000 Jan 15;60(2):342-9. Cancer Res. 2000. PMID: 10667586
-
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.Cancer Res. 2005 Sep 1;65(17):7775-81. doi: 10.1158/0008-5472.CAN-05-0946. Cancer Res. 2005. PMID: 16140945
-
Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.J Biotechnol. 1994 Sep 30;37(2):109-22. doi: 10.1016/0168-1656(94)90002-7. J Biotechnol. 1994. PMID: 7765452 Review.
-
Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1.Biochim Biophys Acta. 2013 Oct;1834(10):2195-204. doi: 10.1016/j.bbapap.2012.10.012. Epub 2012 Oct 31. Biochim Biophys Acta. 2013. PMID: 23123275 Review.
Cited by
-
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.J Mol Med (Berl). 2014 Jan;92(1):65-76. doi: 10.1007/s00109-013-1079-0. Epub 2013 Sep 7. J Mol Med (Berl). 2014. PMID: 24013625
-
Four individually druggable MET hotspots mediate HGF-driven tumor progression.J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27. J Clin Invest. 2014. PMID: 24865428 Free PMC article.
-
Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.Int J Mol Sci. 2017 Sep 13;18(9):1968. doi: 10.3390/ijms18091968. Int J Mol Sci. 2017. PMID: 28902178 Free PMC article.
-
Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.J Biol Chem. 2013 Jun 7;288(23):16529-16537. doi: 10.1074/jbc.M113.457689. Epub 2013 Apr 24. J Biol Chem. 2013. PMID: 23615911 Free PMC article.
-
mAb-Functionalized Biomimetic MamC-Mediated-Magnetoliposomes as Drug Delivery Systems for Cancer Therapy.Int J Mol Sci. 2023 Sep 11;24(18):13958. doi: 10.3390/ijms241813958. Int J Mol Sci. 2023. PMID: 37762260 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous